ABSTRACT
Objective/Research Question: This paper reports the updated results from two landmark trials investigating the difference in recurrence rates between the use of tamoxifen alone, tamoxifen plus ovarian suppression or the aromatase inhibitor exemestane plus ovarian suppression in premenopausal women undergoing definitive treatment for early breast cancer. These studies are the Suppression of Ovarian Function Trial (SOFT) and Tamoxifen and Exemestane Trial (TEXT). 1 These were initiated by the International Breast Cancer Study Group in 2003 to address the value of adding ovarian suppression or using an aromatase inhibitor, to build on the evidence that adjuvant treatment with tamoxifen reduces the recurrence of premenopausal oestrogen receptor (ER)-positive breast cancer, with increasing benefits of extending treatment duration. 2
